Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.

Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- Check2 days agoChange DetectedThe page footer revision label was updated from v3.5.2 to v3.5.3, indicating a backend/site release rather than a modification to the clinical trial’s record history or study details.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded Study Design and Study Status entries in the latest history versions; a previous entry dated 2026-03-05 was removed.SummaryDifference0.5%

- Check38 days agoChange DetectedFooter now shows Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check45 days agoChange DetectedAdded a new Study Status entry to the record history and updated the record to revision v3.4.3 on 2026-03-05.SummaryDifference0.5%

- Check73 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-government-funding notice and the prior Revision: v3.4.1 from the history.SummaryDifference0.8%

Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.